Each year, tens of thousands of children under the age of five succumb to diarrheal diseases caused by enterotoxigenic Escherichia coli (ETEC), with the majority of these cases occurring in low-income countries. In a significant breakthrough, a new ETEC vaccine, ETVAX, has demonstrated promising results in reducing the risk of severe illness, according to a recent study conducted in The Gambia in collaboration with the University of Gothenburg.
The findings, published in The Lancet Infectious Diseases, are based on a randomized, placebo-controlled trial involving approximately 5,000 children aged 6 to 18 months. These children were randomly assigned to receive either the oral vaccine ETVAX or a placebo, and were monitored for up to two years with regular health assessments and sample collection. ETVAX was administered orally in three doses.
Significant Reduction in Severe ETEC Disease
The study revealed that the vaccine reduced the risk of severe ETEC disease by 48 percent. Notably, when children carrying intestinal parasites, which can also cause diarrhea, were excluded from the analysis, the protection rate soared to 80 percent.
“The vaccine reduced the risk of severe ETEC disease by 48 percent, with protection reaching 80 percent in children without intestinal parasites.”
These results underscore the potential of ETVAX to significantly curb the incidence of severe childhood diarrhea, a leading cause of mortality in young children in developing nations.
Importance of Early Vaccination
The study highlighted the importance of early vaccination. Among children vaccinated before nine months of age, the protection rate reached 68 percent, compared to 48 percent in the overall age group. Additionally, the vaccine reduced the risk of severe diarrhea from any cause by 21 percent, a result akin to the effect observed with rotavirus vaccines currently administered to approximately 40 million children in low- and middle-income countries through UNICEF.
“No vaccine-related serious adverse events were observed, and the vaccine generated clear immune responses to the bacterial factors that cause disease.”
Following the evaluation of these results, alongside earlier ETVAX trials, the European Medicines Agency (EMA) has expressed support for advancing ETVAX into a multinational Phase 3 efficacy trial, marking the final and most extensive stage of vaccine development.
Breakthrough After Years of Research
ETVAX is the culmination of several decades of research at the University of Gothenburg, spearheaded by Ann-Mari Svennerholm and her research group, in collaboration with the Swedish biotechnology company Scandinavian Biopharma. The vaccine has undergone evaluation across different age groups and countries in a stepwise development program prior to the current study conducted in Africa.
“For many years, we have worked to develop a vaccine that can protect the youngest children, where the need is greatest,” stated Ann-Mari Svennerholm, senior researcher and professor of infection and immunity at the Sahlgrenska Academy at the University of Gothenburg. “The results indicate that the vaccine has great potential and provide a solid foundation for an international Phase 3 efficacy trial in multiple countries.”
Implications and Future Prospects
The promising results of the ETVAX vaccine trial offer hope for a significant reduction in child mortality due to diarrheal diseases in low-income countries. If the Phase 3 trials confirm these findings, ETVAX could become a critical tool in the global fight against childhood diarrhea, potentially saving thousands of lives each year.
As the vaccine progresses to the next phase of development, researchers and public health officials remain optimistic about its potential impact. The success of ETVAX could pave the way for further innovations in vaccine development, particularly for diseases that disproportionately affect vulnerable populations in developing regions.
The global health community will be closely watching the upcoming Phase 3 trials, as the results could have far-reaching implications for child health initiatives worldwide. With continued support and collaboration, the dream of eradicating severe childhood diarrhea may soon become a reality.
